Literature DB >> 23846857

Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP).

Carol A Tamminga, Elena I Ivleva, Matcheri S Keshavan, Godfrey D Pearlson, Brett A Clementz, Bradley Witte, David W Morris, Jeffrey Bishop, Gunvant K Thaker, John A Sweeney.   

Abstract

OBJECTIVE: Developing categorical diagnoses that have biological meaning within the clinical phenotype of psychosis (schizophrenia, schizoaffective disorder, and bipolar I disorder with psychosis) is as important for developing targeted treatments as for nosological goals. The Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) was formed to examine a broad array of intermediate phenotypes across psychotic disorders and to test the hypothesis that intermediate phenotype characteristics are homogeneous within phenomenologically derived DSM-IV diagnoses.
METHOD: The consortium recruited 933 stable probands with schizophrenia, schizoaffective disorder, or psychotic bipolar I disorder, 1,055 of their first-degree relatives, and 459 healthy comparison subjects for clinical characterization and dense phenotyping. Clinical, psychosocial, and family characteristics were contrasted.
RESULTS: All proband groups showed lower psychosocial functioning than the relatives or comparison group. On average, schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations. The characteristics of schizoaffective disorder were more often similar to schizophrenia than to psychotic bipolar disorder. The rates of lifetime suicide attempts were high across all proband groups, with the highest reported frequencies in the schizoaffective and bipolar groups. Proband family lineages included both families with "pure" psychosis diagnoses and families with mixed schizophrenia-bipolar diagnoses.
CONCLUSIONS: Symptoms, psychosocial functioning, and familial lineage overlap across the three DSM-IV psychosis diagnoses used in B-SNIP. The comingling of psychosis diagnoses within families suggests overlapping genetic determinants across psychoses. These data provide scant evidence for distinct phenotypic clustering around traditional phenomenological diagnoses.

Entities:  

Mesh:

Year:  2013        PMID: 23846857     DOI: 10.1176/appi.ajp.2013.12101339

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  135 in total

Review 1.  Inflammation in Mental Disorders: Is the Microbiota the Missing Link?

Authors:  Sophie Ouabbou; Ying He; Keith Butler; Ming Tsuang
Journal:  Neurosci Bull       Date:  2020-06-27       Impact factor: 5.203

2.  Neural correlates of global and specific cognitive deficits in schizophrenia.

Authors:  Robert J Jirsaraie; Julia M Sheffield; Deanna M Barch
Journal:  Schizophr Res       Date:  2018-06-25       Impact factor: 4.939

3.  Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders.

Authors:  Suraj Sarvode Mothi; Neeraj Tandon; Jaya Padmanabhan; Ian T Mathew; Brett Clementz; Carol Tamminga; Godfrey Pearlson; John Sweeney; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2015-04-19       Impact factor: 4.939

4.  Insomnia and suicidal ideation in nonaffective psychosis.

Authors:  Brian J Miller; Carmen B Parker; Mark H Rapaport; Peter F Buckley; William V McCall
Journal:  Sleep       Date:  2019-02-01       Impact factor: 5.849

5.  Associations between adolescent cannabis use and brain structure in psychosis.

Authors:  Hila Abush; Subroto Ghose; Erin A Van Enkevort; Brett A Clementz; Godfrey D Pearlson; John A Sweeney; Matcheri S Keshavan; Carol A Tamminga; Elena I Ivleva
Journal:  Psychiatry Res Neuroimaging       Date:  2018-03-28       Impact factor: 2.376

6.  Peripheral oxytocin and vasopressin modulates regional brain activity differently in men and women with schizophrenia.

Authors:  Leah H Rubin; Siyi Li; Li Yao; Sarah K Keedy; James L Reilly; Scot K Hill; Jeffrey R Bishop; C Sue Carter; Hossein Pournajafi-Nazarloo; Lauren L Drogos; Elliot Gershon; Godfrey D Pearlson; Carol A Tamminga; Brett A Clementz; Matcheri S Keshavan; Su Lui; John A Sweeney
Journal:  Schizophr Res       Date:  2018-07-06       Impact factor: 4.939

7.  Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia.

Authors:  Shashwath A Meda; Gualberto Ruaño; Andreas Windemuth; Kasey O'Neil; Clifton Berwise; Sabra M Dunn; Leah E Boccaccio; Balaji Narayanan; Mohan Kocherla; Emma Sprooten; Matcheri S Keshavan; Carol A Tamminga; John A Sweeney; Brett A Clementz; Vince D Calhoun; Godfrey D Pearlson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

8.  Multivariate Relationships Between Cognition and Brain Anatomy Across the Psychosis Spectrum.

Authors:  Amanda L Rodrigue; Jennifer E McDowell; Neeraj Tandon; Matcheri S Keshavan; Carol A Tamminga; Godfrey D Pearlson; John A Sweeney; Robert D Gibbons; Brett A Clementz
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2018-03-31

9.  Hippocampal volume is reduced in schizophrenia and schizoaffective disorder but not in psychotic bipolar I disorder demonstrated by both manual tracing and automated parcellation (FreeSurfer).

Authors:  Sara J M Arnold; Elena I Ivleva; Tejas A Gopal; Anil P Reddy; Haekyung Jeon-Slaughter; Carolyn B Sacco; Alan N Francis; Neeraj Tandon; Anup S Bidesi; Bradley Witte; Gaurav Poudyal; Godfrey D Pearlson; John A Sweeney; Brett A Clementz; Matcheri S Keshavan; Carol A Tamminga
Journal:  Schizophr Bull       Date:  2014-02-20       Impact factor: 9.306

10.  Clinical correlates of subsyndromal depression in African American individuals with psychosis: The relationship with positive symptoms and comorbid substance dependence.

Authors:  Emma E M Knowles; Samuel R Mathias; Godfrey D Pearlson; Jennifer Barrett; Josephine Mollon; Dominique Denbow; Katrina Aberzik; Molly Zatony; David C Glahn
Journal:  Schizophr Res       Date:  2018-10-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.